Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 15, 2024

SELL
$0.72 - $1.56 $838 - $1,817
-1,165 Reduced 6.23%
17,528 $25,000
Q3 2023

Nov 14, 2023

SELL
$1.07 - $1.39 $2,165 - $2,813
-2,024 Reduced 9.77%
18,693 $20,000
Q2 2023

Aug 14, 2023

SELL
$1.12 - $1.82 $1,056 - $1,716
-943 Reduced 4.35%
20,717 $26,000
Q4 2022

Feb 14, 2023

SELL
$0.67 - $11.9 $28,444 - $505,202
-42,454 Reduced 66.22%
21,660 $32,000
Q3 2022

Nov 14, 2022

BUY
$1.1 - $12.2 $1,619 - $17,958
1,472 Added 2.35%
64,114 $76,000
Q2 2022

Aug 22, 2022

SELL
$0.67 - $3.19 $3,069 - $14,616
-4,582 Reduced 6.82%
62,642 $71,000
Q1 2022

May 16, 2022

BUY
$2.22 - $3.45 $31 - $48
14 Added 0.02%
67,224 $201,000
Q4 2021

Feb 14, 2022

BUY
$2.36 - $3.57 $9,808 - $14,836
4,156 Added 6.59%
67,210 $179,000
Q3 2021

Nov 15, 2021

BUY
$3.5 - $4.5 $116,889 - $150,286
33,397 Added 112.61%
63,054 $229,000
Q2 2021

Aug 12, 2021

BUY
$3.09 - $4.54 $6,161 - $9,052
1,994 Added 7.21%
29,657 $129,000
Q1 2021

May 17, 2021

BUY
$3.35 - $4.93 $12,954 - $19,064
3,867 Added 16.25%
27,663 $95,000
Q3 2020

Nov 13, 2020

SELL
$1.78 - $4.13 $13,088 - $30,367
-7,353 Reduced 23.61%
23,796 $57,000
Q2 2020

Aug 14, 2020

BUY
$1.41 - $2.05 $4,224 - $6,141
2,996 Added 10.64%
31,149 $57,000
Q1 2020

May 14, 2020

SELL
$1.27 - $3.0 $10,147 - $23,970
-7,990 Reduced 22.11%
28,153 $44,000
Q4 2019

Feb 13, 2020

BUY
$1.6 - $2.43 $9,521 - $14,460
5,951 Added 19.71%
36,143 $78,000
Q4 2018

Feb 15, 2019

BUY
$2.08 - $3.36 $5,200 - $8,400
2,500 Added 9.03%
30,192 $69,000
Q2 2018

Aug 10, 2018

BUY
$2.83 - $4.11 $4,015 - $5,832
1,419 Added 5.4%
27,692 $79,000
Q1 2018

May 17, 2018

SELL
$3.54 - $4.54 $33,191 - $42,567
-9,376 Reduced 26.3%
26,273 $93,000
Q4 2017

Feb 13, 2018

BUY
$3.23 - $4.3 $115,146 - $153,290
35,649
35,649 $137,000

Others Institutions Holding RIGL

About RIGEL PHARMACEUTICALS INC


  • Ticker RIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 172,836,000
  • Market Cap $2.96B
  • Description
  • Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...
More about RIGL
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.